BRWA
PSTV

B. Riley Wealth Advisors’s Plus Therapeutics PSTV Stock Holding History

B. Riley Wealth Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-67
Closed -$7.92K – 1600
2022
Q4 		$7.92K Buy
+67
New +$10.7K ﹤0.01% 1472
2015
Q1 		– Hold
0
– – – 1636
2014
Q4 		– Hold
0
– – – 3733
2014
Q3 		– Hold
0
– -$2.85K – 1586
2014
Q2 		– Hold
0
– – – 2171

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GVAG
Great Valley Advisor Group Wilmington, Delaware $5.5B AUM 20.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

B. Riley Wealth Advisors's PSTV Position: Q1 2023 in Review

B. Riley Wealth Advisors sold out of Plus Therapeutics (PSTV) in Q1 2023, closing a stake of 67 shares — an estimated $7.92K sold.

B. Riley Wealth Advisors first reported a position in PSTV in Q4 2022 and held it in 1 quarter. The position peaked at $7.92K in Q4 2022. 16 funds tracked by Wall St. Rank hold PSTV as of Q1 2023.

  • B. Riley Wealth Advisors reported no remaining Plus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 67 Plus Therapeutics shares in Q1 2023, an estimated $7.92K.
  • B. Riley Wealth Advisors first reported a position in Plus Therapeutics in Q4 2022 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Plus Therapeutics position peaked at $7.92K in Q4 2022.
  • 16 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2023.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2023, filed 17 May 2023.